Glaukos Corporation (NYSE:GKOS – Get Free Report) COO Joseph Gilliam sold 861 shares of the company’s stock in a transaction dated Monday, November 16th. The shares were sold at an average price of $250.00, for a total transaction of $215,250.00. Following the sale, the chief operating officer owned 71,602 shares of the company’s stock, valued at approximately $17,900,500. The trade was a 1.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Glaukos Trading Down 4.4%
Shares of NYSE:GKOS traded down $10.66 on Wednesday, reaching $232.59. 1,132,309 shares of the company traded hands, compared to its average volume of 1,909,791. The business’s 50-day simple moving average is $188.17 and its 200 day simple moving average is $148.89. The company has a quick ratio of 4.09, a current ratio of 4.57 and a debt-to-equity ratio of 0.09. Glaukos Corporation has a 52 week low of $91.83 and a 52 week high of $255.18.
Glaukos (NYSE:GKOS – Get Free Report) last issued its earnings results on Wednesday, October 28th. The medical instruments supplier reported $0.47 earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.57. Glaukos had a negative return on equity of 0.97% and a negative net margin of 24.60%. The company had revenue of $211.03 million during the quarter, compared to analysts’ expectations of $168.04 million. During the same period in the prior year, the business posted ($0.16) EPS. Glaukos’s quarterly revenue was up 58.0% compared to the same quarter last year. Analysts expect that Glaukos Corporation will post 0.50 earnings per share for the current year.
Hedge Funds Weigh In On Glaukos
Wall Street Analysts Forecast Growth
GKOS has been the topic of several recent analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Glaukos in a report on Thursday, October 15th. Zacks Research upgraded shares of Glaukos from a “hold” rating to a “strong-buy” rating in a report on Wednesday, October 28th. BTIG Research increased their price target on shares of Glaukos from $234.00 to $252.00 and gave the company a “buy” rating in a research report on Monday. Needham & Company LLC boosted their price objective on shares of Glaukos from $201.00 to $251.00 and gave the company a “buy” rating in a research report on Thursday, October 29th. Finally, Wall Street Zen raised shares of Glaukos from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 7th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $218.00.
Check Out Our Latest Research Report on GKOS
Glaukos Company Profile
Glaukos Corporation is an ophthalmic medical technology company that develops and commercializes treatments for glaucoma and other eye disorders. Its portfolio includes minimally invasive glaucoma surgery (MIGS) devices, such as the iStent family, and iDose TR, an implant designed to deliver glaucoma medication inside the eye over an extended period. The company also offers products for corneal disorders, including technology used in corneal cross-linking procedures to treat keratoconus and other conditions that weaken the cornea.
Read More
- Five stocks we like better than Glaukos
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.
